Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website.

  • 1.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 2.

    Social Security Administration. Period Life Table. 2009. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed March 10 2014.

    • Search Google Scholar
    • Export Citation
  • 3.

    HowardDH. Life expectancy and the value of early detection. J Health Econ2005;24:891906.

  • 4.

    D’AmicoAVWhittingtonRMalkowiczSB. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol1999;17:168172.

    • Search Google Scholar
    • Export Citation
  • 5.

    D’AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002;95:281286.

    • Search Google Scholar
    • Export Citation
  • 6.

    D’AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998;280:969974.

    • Search Google Scholar
    • Export Citation
  • 7.

    ReeseACPierorazioPMHanMPartinAW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology2012;80:10751079.

    • Search Google Scholar
    • Export Citation
  • 8.

    Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed March 24 2014.

  • 9.

    MakarovDVTrockBJHumphreysEB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology2007;69:10951101.

    • Search Google Scholar
    • Export Citation
  • 10.

    KattanMWEasthamJAWheelerTM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003;170:17921797.

    • Search Google Scholar
    • Export Citation
  • 11.

    Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed March 24 2014.

    • Search Google Scholar
    • Export Citation
  • 12.

    StephensonAJScardinoPTEasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006;98:715717.

    • Search Google Scholar
    • Export Citation
  • 13.

    StephensonAJKattanMWEasthamJA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol2009;27:43004305.

    • Search Google Scholar
    • Export Citation
  • 14.

    GraefenMHaeseAPichlmeierU. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol2001;165:857863.

    • Search Google Scholar
    • Export Citation
  • 15.

    OhoriMKattanMWKohH. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol2004;171:18441849; discussion 1849.

    • Search Google Scholar
    • Export Citation
  • 16.

    SteuberTGraefenMHaeseA. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol2006;175:939944; discussion 944.

    • Search Google Scholar
    • Export Citation
  • 17.

    BrigantiAChunFKSaloniaA. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol2007;51:112119; discussion 119-120.

    • Search Google Scholar
    • Export Citation
  • 18.

    KattanMWPottersLBlaskoJC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology2001;58:393399.

    • Search Google Scholar
    • Export Citation
  • 19.

    PottersLMorgensternCCalugaruE. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol2008;179:S2024.

    • Search Google Scholar
    • Export Citation
  • 20.

    ZelefskyMJKattanMWFearnP. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology2007;70:283287.

    • Search Google Scholar
    • Export Citation
  • 21.

    JeldresCSuardiNWalzJ. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol2008;54:13061313.

    • Search Google Scholar
    • Export Citation
  • 22.

    LeeSJLindquistKSegalMRCovinskyKE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA2006;295:801808.

    • Search Google Scholar
    • Export Citation
  • 23.

    StephensonAJScardinoPTKattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007;25:20352041.

    • Search Google Scholar
    • Export Citation
  • 24.

    DearnaleyDPKhooVSNormanAR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet1999;353:267272.

    • Search Google Scholar
    • Export Citation
  • 25.

    KhooVS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol)2005;17:560571.

    • Search Google Scholar
    • Export Citation
  • 26.

    D’AmicoAVCoteKLoffredoM. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol2002;20:45674573.

    • Search Google Scholar
    • Export Citation
  • 27.

    D’AmicoAVMoulJWCarrollPR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003;95:13761383.

    • Search Google Scholar
    • Export Citation
  • 28.

    JohanssonJEHolmbergLJohanssonS. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA1997;277:467471.

    • Search Google Scholar
    • Export Citation
  • 29.

    van den BerghRCEssink-BotMLRoobolMJ. Anxiety and distress during active surveillance for early prostate cancer. Cancer2009;115:38683878.

    • Search Google Scholar
    • Export Citation
  • 30.

    SakrWAGrignonDJCrissmanJD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo1994;8:439443.

    • Search Google Scholar
    • Export Citation
  • 31.

    ThompsonIMPaulerDKGoodmanPJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004;350:22392246.

    • Search Google Scholar
    • Export Citation
  • 32.

    SchroderFHHugossonJRoobolMJ. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med2012;366:981990.

  • 33.

    SchroderFHHugossonJRoobolMJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009;360:13201328.

  • 34.

    KlotzL. Active surveillance for prostate cancer: for whom?J Clin Oncol2005;23:81658169.

  • 35.

    AndrioleGLCrawfordEDGrubbRL3rd. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009;360:13101319.

  • 36.

    AndrioleGLBostwickDGBrawleyOW. Effect of dutasteride on the risk of prostate cancer. N Engl J Med2010;362:11921202.

  • 37.

    AndrioleGLCrawfordEDGrubbRL3rd. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012;104:125132.

    • Search Google Scholar
    • Export Citation
  • 38.

    SandblomGVarenhorstERosellJ. Randomised prostate cancer screening trial: 20 year follow-up. BMJ2011;342:d1539.

  • 39.

    HugossonJCarlssonSAusG. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol2010;11:725732.

    • Search Google Scholar
    • Export Citation
  • 40.

    MillerDCGruberSBHollenbeckBK. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst2006;98:11341141.

    • Search Google Scholar
    • Export Citation
  • 41.

    DraismaGEtzioniRTsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009;101:374383.

    • Search Google Scholar
    • Export Citation
  • 42.

    DraismaGBoerROttoSJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst2003;95:868878.

    • Search Google Scholar
    • Export Citation
  • 43.

    EpsteinJIWalshPCCarmichaelMBrendlerCB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994;271:368374.

    • Search Google Scholar
    • Export Citation
  • 44.

    BastianPJMangoldLAEpsteinJIPartinAW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer2004;101:20012005.

    • Search Google Scholar
    • Export Citation
  • 45.

    ChunFKHaeseAAhyaiSA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer2008;113:701709.

    • Search Google Scholar
    • Export Citation
  • 46.

    BastianPJCarterBHBjartellA. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol2009;55:13211330.

    • Search Google Scholar
    • Export Citation
  • 47.

    SandaMGKaplanID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA2009;301:21412151.

  • 48.

    SundiDRossAEHumphreysEB. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?J Clin Oncol2013;31:29912997.

    • Search Google Scholar
    • Export Citation
  • 49.

    CarterHBKettermannAWarlickC. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol2007;178:23592364; discussion 2364-2355.

    • Search Google Scholar
    • Export Citation
  • 50.

    Dall’EraMAKonetyBRCowanJE. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer2008;112:26642670.

    • Search Google Scholar
    • Export Citation
  • 51.

    KlotzLZhangLLamA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010;28:126131.

    • Search Google Scholar
    • Export Citation
  • 52.

    SheridanTBCarterHBWangW. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol2008;179:901904; discussion 904-905.

    • Search Google Scholar
    • Export Citation
  • 53.

    TosoianJJTrockBJLandisP. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011;29:21852190.

    • Search Google Scholar
    • Export Citation
  • 54.

    LoblawAZhangLLamA. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol2010;184:19421946.

    • Search Google Scholar
    • Export Citation
  • 55.

    RossAELoebSLandisP. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol2010;28:28102816.

    • Search Google Scholar
    • Export Citation
  • 56.

    KlotzL. Point: active surveillance for favorable risk prostate cancer. J Natl Compr Canc Netw2007;5:693698.

  • 57.

    FelicianoJTeperEFerrandinoM. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis?J Urol2008;179:952955; discussion 955.

    • Search Google Scholar
    • Export Citation
  • 58.

    FujitaKLandisPMcNeilBKPavlovichCP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol2009;182:26642669.

    • Search Google Scholar
    • Export Citation
  • 59.

    Bill-AxelsonAHolmbergLRuutuM. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2011;364:17081717.

    • Search Google Scholar
    • Export Citation
  • 60.

    PierorazioPMRossAELinBM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int2012;110:11221128.

    • Search Google Scholar
    • Export Citation
  • 61.

    ChadeDCEasthamJGraefenM. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol2012;61:961971.

    • Search Google Scholar
    • Export Citation
  • 62.

    ShekarrizBUpadhyayJPontesJE. Salvage radical prostatectomy. Urol Clin North Am2001;28:545553.

  • 63.

    KleinEABiancoFJSerioAM. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol2008;179:22122216; discussion 2216-2217.

    • Search Google Scholar
    • Export Citation
  • 64.

    BeggCBRiedelERBachPB. Variations in morbidity after radical prostatectomy. N Engl J Med2002;346:11381144.

  • 65.

    HerrellSDSmithJAJr. Robotic-assisted laparoscopic prostatectomy: what is the learning curve?Urology2005;66:105107.

  • 66.

    SmithJAJr.HerrellSD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages?J Clin Oncol2005;23:81708175.

    • Search Google Scholar
    • Export Citation
  • 67.

    HuJCGuXLipsitzSR. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA2009;302:15571564.

  • 68.

    ParsonsJKBennettJL. Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy. Urology2008;72:412416.

  • 69.

    FicarraVNovaraGRosenRC. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol2012;62:405417.

    • Search Google Scholar
    • Export Citation
  • 70.

    FicarraVNovaraGAhleringTE. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol2012;62:418430.

    • Search Google Scholar
    • Export Citation
  • 71.

    ResnickMJKoyamaTFanKH. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med2013;368:436445.

  • 72.

    NamRKCheungPHerschornS. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol2014;15:223231.

    • Search Google Scholar
    • Export Citation
  • 73.

    FreireMPWeinbergACLeiY. Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol2009;56:972980.

    • Search Google Scholar
    • Export Citation
  • 74.

    AbelEJMastersonTAWarnerJN. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology2009;73:13361340.

    • Search Google Scholar
    • Export Citation
  • 75.

    DavisJWChangDWChevrayP. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol2009;55:11351143.

    • Search Google Scholar
    • Export Citation
  • 76.

    CagiannosIKarakiewiczPEasthamJA. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol2003;170:17981803.

    • Search Google Scholar
    • Export Citation
  • 77.

    BrigantiABluteMLEasthamJH. Pelvic lymph node dissection in prostate cancer. Eur Urol2009;55:12511265.

  • 78.

    HeidenreichAOhlmannCHPolyakovS. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol2007;52:2937.

    • Search Google Scholar
    • Export Citation
  • 79.

    MastersonTABiancoFJJr.VickersAJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol2006;175:13201324; discussion 1324-1325.

    • Search Google Scholar
    • Export Citation
  • 80.

    JoslynSAKonetyBR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology2006;68:121125.

    • Search Google Scholar
    • Export Citation
  • 81.

    AllafMEPalapattuGSTrockBJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol2004;172:18401844.

    • Search Google Scholar
    • Export Citation
  • 82.

    BaderPBurkhardFCMarkwalderRStuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol2003;169:849854.

    • Search Google Scholar
    • Export Citation
  • 83.

    DaneshmandSQuekMLSteinJP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol2004;172:22522255.

    • Search Google Scholar
    • Export Citation
  • 84.

    WagnerMSokoloffMDaneshmandS. The role of pelvic lymphadenectomy for prostate cancer—therapeutic?J Urol2008;179:408413.

  • 85.

    HanlonALWatkins BrunerDPeterRHanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys2001;49:5159.

    • Search Google Scholar
    • Export Citation
  • 86.

    KoperPCStroomJCvan PuttenWL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys1999;43:727734.

    • Search Google Scholar
    • Export Citation
  • 87.

    MichalskiJMBaeKRoachM. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys2010;76:1422.

    • Search Google Scholar
    • Export Citation
  • 88.

    JacobsBLZhangYSchroeckFR. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA2013;309:25872595.

    • Search Google Scholar
    • Export Citation
  • 89.

    ZelefskyMJLevinEJHuntM. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2008;70:11241129.

    • Search Google Scholar
    • Export Citation
  • 90.

    JaniABSuACorreaDGratzleJ. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis2007;10:8286.

    • Search Google Scholar
    • Export Citation
  • 91.

    JacobsBLZhangYSkolarusTA. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol2014;65:162168.

    • Search Google Scholar
    • Export Citation
  • 92.

    PeetersSTHeemsbergenWDKoperPC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006;24:19901996.

    • Search Google Scholar
    • Export Citation
  • 93.

    PollackAZagarsGKStarkschallG. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002;53:10971105.

    • Search Google Scholar
    • Export Citation
  • 94.

    ZietmanALDeSilvioMLSlaterJD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2005;294:12331239.

    • Search Google Scholar
    • Export Citation
  • 95.

    KubanDATuckerSLDongL. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008;70:6774.

    • Search Google Scholar
    • Export Citation
  • 96.

    XuNRossiPJJaniAB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol2011;34:1115.

  • 97.

    EadeTNHanlonALHorwitzEM. What dose of external-beam radiation is high enough for prostate cancer?Int J Radiat Oncol Biol Phys2007;68:682689.

    • Search Google Scholar
    • Export Citation
  • 98.

    PollackAWalkerGHorwitzEM. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol2013;31:38603868.

    • Search Google Scholar
    • Export Citation
  • 99.

    ArcangeliSStrigariLGomelliniS. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys2012;84:11721178.

    • Search Google Scholar
    • Export Citation
  • 100.

    PotoskyALDavisWWHoffmanRM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst2004;96:13581367.

    • Search Google Scholar
    • Export Citation
  • 101.

    SandaMGDunnRLMichalskiJ. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med2008;358:12501261.

    • Search Google Scholar
    • Export Citation
  • 102.

    NguyenPLD’AmicoAVLeeAKSuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer2007;110:14171428.

    • Search Google Scholar
    • Export Citation
  • 103.

    CritzFABentonJBShrakePMerlinML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol2013;189:878883.

    • Search Google Scholar
    • Export Citation
  • 104.

    BollaMVan TienhovenGWardeP. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol2010;11:10661073.

    • Search Google Scholar
    • Export Citation
  • 105.

    PilepichMVWinterKLawtonCA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys2005;61:12851290.

    • Search Google Scholar
    • Export Citation
  • 106.

    WardePMasonMDingK. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet2011;378:21042111.

    • Search Google Scholar
    • Export Citation
  • 107.

    WidmarkAKleppOSolbergA. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet2009;373:301308.

    • Search Google Scholar
    • Export Citation
  • 108.

    DasuA. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?Clin Oncol (R Coll Radiol)2007;19:289301.

    • Search Google Scholar
    • Export Citation
  • 109.

    BuyyounouskiMKPriceRAJr.HarrisEE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys2010;76:12971304.

    • Search Google Scholar
    • Export Citation
  • 110.

    FreemanDEKingCR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol2011;6:3.

  • 111.

    KangJKChoCKChoiCW. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori2011;97:4348.

  • 112.

    MadsenBLHsiRAPhamHT. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys2007;67:10991105.

    • Search Google Scholar
    • Export Citation
  • 113.

    ChenLNSuySUhmS. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol2013;8:58.

    • Search Google Scholar
    • Export Citation
  • 114.

    KatzAJSantoroMDiblasioFAshleyR. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol2013;8:118.

    • Search Google Scholar
    • Export Citation
  • 115.

    KingCRFreemanDKaplanI. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol2013;109:217221.

    • Search Google Scholar
    • Export Citation
  • 116.

    BrachmanDGThomasTHilbeJBeyerDC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys2000;48:111117.

    • Search Google Scholar
    • Export Citation
  • 117.

    MassonSPersadRBahlA. HDR brachytherapy in the management of high-risk prostate cancer. Adv Urol2012;2012:980841.

  • 118.

    MerrickGSButlerWMWallnerKE. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology2004;64:754759.

    • Search Google Scholar
    • Export Citation
  • 119.

    EadeTNHorwitzEMRuthK. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys2008;71:338345.

    • Search Google Scholar
    • Export Citation
  • 120.

    WongWWVoraSASchildSE. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer2009;115:55965606.

    • Search Google Scholar
    • Export Citation
  • 121.

    LeeNWuuCSBrodyR. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys2000;48:14571460.

    • Search Google Scholar
    • Export Citation
  • 122.

    HenkelTOKahmannF. Permanent brachytherapy: prostate seed implants as an out-patient treatment. Arch Ital Urol Androl2000;72:295301.

  • 123.

    NagSBiceWDeWyngaertK. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys2000;46:221230.

    • Search Google Scholar
    • Export Citation
  • 124.

    Al-SalihiOMitraAPayneH. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis2006;9:370373.

    • Search Google Scholar
    • Export Citation
  • 125.

    FangFMWangYMWangCJ. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol2008;38:474479.

    • Search Google Scholar
    • Export Citation
  • 126.

    PietersBRvan de KamerJBvan HertenYR. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol2008;88:4652.

    • Search Google Scholar
    • Export Citation
  • 127.

    SoumarovaRHomolaLPerkovaHStursaM. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori2007;93:3744.

    • Search Google Scholar
    • Export Citation
  • 128.

    SathyaJRDavisIRJulianJA. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol2005;23:11921199.

    • Search Google Scholar
    • Export Citation
  • 129.

    HoskinPJMotohashiKBownesP. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol2007;84:114120.

    • Search Google Scholar
    • Export Citation
  • 130.

    HoskinPJRojasAMBownesPJ. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol2012;103:217222.

    • Search Google Scholar
    • Export Citation
  • 131.

    ShenXKeithSWMishraMV. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys2012;83:11541159.

    • Search Google Scholar
    • Export Citation
  • 132.

    BittnerNMerrickGSButlerWM. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy2012;11:250255.

    • Search Google Scholar
    • Export Citation
  • 133.

    Martinez-MongeRMorenoMCiervideR. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys2012;82:e469476.

    • Search Google Scholar
    • Export Citation
  • 134.

    D’AmicoAVMoranBJBraccioforteMH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol2009;27:39233928.

    • Search Google Scholar
    • Export Citation
  • 135.

    DemanesDJBrandtDSchourLHillDR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol2009;32:342347.

    • Search Google Scholar
    • Export Citation
  • 136.

    DattoliMWallnerKTrueL. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol2010;2010:471375.

    • Search Google Scholar
    • Export Citation
  • 137.

    HoskinP. High dose rate brachytherapy for prostate cancer. Cancer Radiother2008;12:512514.

  • 138.

    GrillsISMartinezAAHollanderM. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol2004;171:10981104.

    • Search Google Scholar
    • Export Citation
  • 139.

    VargasCGhilezanMHollanderM. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol2005;174:882887.

    • Search Google Scholar
    • Export Citation
  • 140.

    CoenJJZietmanAL. Proton radiation for localized prostate cancer. Nat Rev Urol2009;6:324330.

  • 141.

    YuJBSoulosPRHerrinJ. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst2013;105:2532.

    • Search Google Scholar
    • Export Citation
  • 142.

    CoenJJPalyJJNiemierkoA. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2012;82:e201209.

    • Search Google Scholar
    • Export Citation
  • 143.

    AllenAMPawlickiTDongL. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol2012;103:811.

    • Search Google Scholar
    • Export Citation
  • 144.

    BabaianRJDonnellyBBahnD. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol2008;180:19932004.

    • Search Google Scholar
    • Export Citation
  • 145.

    BahnDde Castro AbreuALGillIS. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol2012;62:5563.

    • Search Google Scholar
    • Export Citation
  • 146.

    DonnellyBJSalikenJCBrasherPM. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer2010;116:323330.

    • Search Google Scholar
    • Export Citation
  • 147.

    RobinsonJWDonnellyBJSieverJE. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer2009;115:46954704.

    • Search Google Scholar
    • Export Citation
  • 148.

    ChinJLAl-ZahraniAAAutran-GomezAM. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol2012;188:11701175.

    • Search Google Scholar
    • Export Citation
  • 149.

    BarretEAhallalYSanchez-SalasR. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol2013;63:618622.

  • 150.

    Lu-YaoGLAlbertsenPCMooreDF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA2008;300:173181.

    • Search Google Scholar
    • Export Citation
  • 151.

    D’AmicoAVChenMHRenshawAA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA2008;299:289295.

    • Search Google Scholar
    • Export Citation
  • 152.

    DenhamJWSteiglerALambDS. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol2011;12:451459.

    • Search Google Scholar
    • Export Citation
  • 153.

    JonesCUHuntDMcGowanDG. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med2011;365:107118.

  • 154.

    RoachM3rdBaeKSpeightJ. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol2008;26:585591.

    • Search Google Scholar
    • Export Citation
  • 155.

    HorwitzEMBaeKHanksGE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008;26:24972504.

    • Search Google Scholar
    • Export Citation
  • 156.

    BollaMde ReijkeTMVan TienhovenG. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med2009;360:25162527.

    • Search Google Scholar
    • Export Citation
  • 157.

    SouhamiLBaeKPilepichMSandlerH. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol2009;27:21372143.

    • Search Google Scholar
    • Export Citation
  • 158.

    KumarSShelleyMHarrisonC. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev2006:CD006019.

    • Search Google Scholar
    • Export Citation
  • 159.

    MessingEMManolaJYaoJ. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol2006;7:472479.

    • Search Google Scholar
    • Export Citation
  • 160.

    LoblawDAVirgoKSNamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007;25:15961605.

    • Search Google Scholar
    • Export Citation
  • 161.

    WongYNFreedlandSEglestonB. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol2009;27:100105.

  • 162.

    McLeodDGIversenPSeeWA. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int2006;97:247254.

    • Search Google Scholar
    • Export Citation
  • 163.

    McLeodDGSeeWAKlimbergI. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol2006;176:7580.

    • Search Google Scholar
    • Export Citation
  • 164.

    BrigantiAPassoniNFerrariM. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol2010;57:551558.

    • Search Google Scholar
    • Export Citation
  • 165.

    WolfJSJr.CherMDall’eraM. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol1995;153:993999.

    • Search Google Scholar
    • Export Citation
  • 166.

    DickinsonLAhmedHUAllenC. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol2011;59:477494.

    • Search Google Scholar
    • Export Citation
  • 167.

    Dall’EraMAAlbertsenPCBangmaC. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol2012;62:976983.

    • Search Google Scholar
    • Export Citation
  • 168.

    PoundCRPartinAWEisenbergerMA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999;281:15911597.

    • Search Google Scholar
    • Export Citation
  • 169.

    ThompsonIMTangenCMParadeloJ. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol2009;181:956962.

    • Search Google Scholar
    • Export Citation
  • 170.

    ThompsonIMJr.TangenCMParadeloJ. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA2006;296:23292335.

    • Search Google Scholar
    • Export Citation
  • 171.

    SwansonGPGoldmanBTangenCM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol2008;180:24532457; discussion 2458.

    • Search Google Scholar
    • Export Citation
  • 172.

    Van der KwastTHBollaMVan PoppelH. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol2007;25:41784186.

    • Search Google Scholar
    • Export Citation
  • 173.

    WiegelTBottkeDSteinerU. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol2009;27:29242930.

    • Search Google Scholar
    • Export Citation
  • 174.

    Da PozzoLFCozzariniCBrigantiA. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol2009;55:10031011.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 465 465 31
PDF Downloads 89 89 6
EPUB Downloads 0 0 0